Drug · CHEMBL25

ASPIRIN

7 sourcespipelines-2026-09-18-0.3.1

Cite this record

ConductScience Library. ASPIRIN. Drugs and targets, record CHEMBL25. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL25

On this page

Drug

Names and IDs as ChEMBL gives them, through Open Targets.

Name: ASPIRIN; ChEMBL
ChEMBL ID: CHEMBL25; ChEMBL
Type: Small molecule; ChEMBL
Brand names: 8-hour bayer, Acetosalic acid, Acetylsalic acid, Alka rapid, Anadin all night, Angettes 75, Aspirin component of -pc, Aspirin component of aggrenox, Aspirin component of axotal, Aspirin component of azdone, Aspirin component of carisoprodol compound, Aspirin component of clopidogrel/acetylsalicylic acid, Aspirin component of codoxy, Aspirin component of darvon compound, Aspirin component of duocover, Aspirin component of duoplavin, Aspirin component of equagesic, Aspirin component of excedrin, Aspirin component of fiorinal, Aspirin component of invagesic, Aspirin component of invagesic forte, Aspirin component of lanorinal, Aspirin component of mepro-, Aspirin component of micrainin, Aspirin component of norgesic, Aspirin component of orphengesic, Aspirin component of orphengesic forte, Aspirin component of pa-32540, Aspirin component of percodan, Aspirin component of percodan-demi, Aspirin component of pl2200, Aspirin component of pravigard pac, Aspirin component of q-gesic, Aspirin component of robaxisal, Aspirin component of roxiprin, Aspirin component of soma compound, Aspirin component of synalgos-dc, Aspirin component of talwin compound, Aspirin component of vicoprin, Aspirin component of yosprala, Aspro clr, Bayer extra strength aspirin for migraine pain, Danamep, Disprin cv, Disprin direct, Durlaza, Enprin, Equi-prin, Gencardia, Levius, Max strgh aspro clr, Measurin, Micropirin ec, Nu-seals 300, Nu-seals 600, Nu-seals 75, Nu-seals cardio 75, Paynocil, Platet, Platet 300, Postmi 300, Postmi 75, Salicylic acid acetate, Vazalore; ChEMBL
Other names: Acetyl salicylate, Acetylsalicylic acid, Acetylsalicylic acid (who-ip), Acetylsalicylicum acidum, Acidum acetylsalicylicum, Acidum acetylsalicylicum (who-ip), BAY1019036, Benzoic acid, 2-(acetyloxy)-, NSC-27223, NSC-406186; ChEMBL
Other form: ASPIRIN DL-LYSINE, CHEMBL1697753; Drugs and targets
DrugBank: DB00945; DrugBank
InChIKey: BSYNRYMUTXBXSQ-UHFFFAOYSA-N; ChEMBL
Open Targets' highest stage: Approval, for 30 of its 184 diseases, from ATC, DailyMed, EMA Human Drugs, PMDA and TTD; Open Targets

Targets2

The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.

Target	Protein	Mechanism	Action	Gene in Genes
PTGS1	Cyclooxygenase	Cyclooxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/5742
PTGS2	Cyclooxygenase	Cyclooxygenase inhibitor	INHIBITOR	https://conductscience.org/library/genes/5743

Source ChEMBL

Diseases184

The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.

Disease	Open Targets' stage	Stage reported by	Reports	Of them trials	Its drugs
coronary artery disorder	Approval	DailyMed	39	38	https://conductscience.org/library/drugs?q=MONDO_0005010
ischemic stroke	Phase 3	ClinicalTrials.gov	36	36	https://conductscience.org/library/drugs?q=MONDO_1060198
acute coronary syndrome	Approval	EMA Human Drugs and PMDA	41	34	https://conductscience.org/library/drugs?q=MONDO_0005542
myocardial infarction	Approval	DailyMed, EMA Human Drugs, PMDA and TTD	40	30	https://conductscience.org/library/drugs?q=MONDO_0005068
stroke disorder	Approval	DailyMed	37	30	https://conductscience.org/library/drugs?q=MONDO_0005098
transient ischemic attack	Approval	PMDA	24	20	https://conductscience.org/library/drugs?q=MONDO_0005264
cardiovascular disorder	Approval	TTD	20	18	https://conductscience.org/library/drugs?q=MONDO_0004995
peripheral arterial disease	Phase 3	ClinicalTrials.gov	14	14	https://conductscience.org/library/drugs?q=MONDO_0005386
type 2 diabetes mellitus	Phase 3	ClinicalTrials.gov	14	14	https://conductscience.org/library/drugs?q=MONDO_0005148
COVID-19	Phase 3	ClinicalTrials.gov	12	12	https://conductscience.org/library/drugs?q=MONDO_0100096

1 to 10 of 184Source Open Targets

See all 184 diseases

Trials1,187

Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs. 5 more rest on that reading alone and are shown because the trials' posted result groups or NLM's indexing of their papers name the drug. 11 more that Open Targets linked to it are not shown, since the release's checks do not confirm them.

Trial	Title	Phase	Participants	Results first posted	Named as	Linked by	Source
NCT00000479	Women's Health Study (WHS): A Randomized Trial of Low-dose Aspirin and Vitamin E in the Primary Prevention of Cardiovascular Disease and Cancer	Phase 3	39,876	2012-06-13	aspirin	Its name	ClinicalTrials.gov
NCT01776424	Rivaroxaban for the Prevention of Major Cardiovascular Events in Coronary or Peripheral Artery Disease	Phase 3	27,395	2018-10-05	aspirin	Its name	ClinicalTrials.gov
NCT00977938	The Dual Antiplatelet Therapy Study (DAPT Study)	Phase 4	25,682	2015-10-22	aspirin	Its name	ClinicalTrials.gov
NCT00335452	Clopidogrel Optimal Loading Dose Usage to Reduce Recurrent EveNTs/Optimal Antiplatelet Strategy for InterventionS	Phase 3	25,086	2010-10-07	aspirin	Its name	ClinicalTrials.gov
NCT00153062	PRoFESS - Prevention Regimen For Effectively Avoiding Second Strokes	Phase 4	20,332	2009-09-02	aspirin	Its name	ClinicalTrials.gov
NCT01813435	GLOBAL LEADERS: A Clinical Study Comparing Two Forms of Anti-platelet Therapy After Stent Implantation	Phase 3	15,991	2019-07-05	aspirin	Its name	ClinicalTrials.gov
NCT00135226	ASCEND: A Study of Cardiovascular Events iN Diabetes	Phase 4	15,480	2019-04-26	aspirin	Its name	ClinicalTrials.gov
NCT02697916	Aspirin Dosing: A Patient-Centric Trial Assessing Benefits and Long-term		15,076	2021-07-01	aspirin	Its name	ClinicalTrials.gov
NCT01994720	[SOCRATES -Acute Stroke Or Transient IsChaemic Attack TReated With Aspirin or Ticagrelor and Patient OutcomES]	Phase 3	13,307	2017-06-12	acetylsalicylic acid	Its name	ClinicalTrials.gov
NCT00501059	A Study to Assess the Efficacy and Safety of Enteric-Coated Acetylsalicylic Acid in Patients at Moderate Risk of Cardiovascular Disease	Phase 3	12,546	2018-01-08	acetylsalicylic acid	Its name	ClinicalTrials.gov

1 to 10 of 1,187

See all 1,187 trials

Comparisons in its trials358

Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.

Comparison	Group 1, with the outcome	Group 2, with the outcome	Participants	Trial	Source
Telmisartan vs Placebo: Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Telmisartan vs. Placebo Only)	880 of 10,146	934 of 10,186	20,332	NCT00153062	Trial comparisons
Telmisartan vs Placebo: Composite Outcome of Stroke, Myocardial Infarction, Vascular Death, or New or Worsening Congestive Heart Failure (CHF) (Telmisartan vs. Placebo Only)	1,367 of 10,146	1,463 of 10,186	20,332	NCT00153062	Trial comparisons
Aspirin + Extended Release Dipyridamole vs Clopidogrel: Composite Outcome of Stroke, Myocardial Infarction (MI), or Vascular Death (Antiplatelet Comparison Only)	1,333 of 10,181	1,333 of 10,151	20,332	NCT00153062	Trial comparisons
Aspirin + Extended Release Dipyridamole vs Clopidogrel: Number of Patients With First Recurrent Stroke of Any Type, Fatal or Nonfatal (Antiplatelet Comparison Only)	916 of 10,181	898 of 10,151	20,332	NCT00153062	Trial comparisons
Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Composite of All-cause Mortality or Non-fatal New Q-wave Myocardial Infarction (MI)	304 of 7,980	349 of 7,988	15,968	NCT01813435	Trial comparisons
Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With All-cause Mortality	224 of 7,980	253 of 7,988	15,968	NCT01813435	Trial comparisons
Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With Myocardial Infarction	248 of 7,980	250 of 7,988	15,968	NCT01813435	Trial comparisons
Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Myocardial Revascularisation	739 of 7,980	793 of 7,988	15,968	NCT01813435	Trial comparisons
Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With New Q-wave Myocardial Infarction	83 of 7,980	103 of 7,988	15,968	NCT01813435	Trial comparisons
Experimental Treatment Strategy vs Reference Treatment Strategy: Number of Participants With a Bleeding Academic Research Consortium (BARC) 3 or 5 Bleeding	163 of 7,980	169 of 7,988	15,968	NCT01813435	Trial comparisons

1 to 10 of 358

See all 358 comparisons in its trials

Papers from its trials1,552

The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.

PMID	Listed as	Trials listing it	Source
41921522	RESULT	1	PubMed
40886716	RESULT	1	PubMed
40383127	RESULT	1	PubMed
40360262	RESULT	1	PubMed
40261382	RESULT	1	PubMed
40010818	RESULT	1	PubMed
39501183	RESULT	1	PubMed
38877813	RESULT	1	PubMed
38670139	RESULT	1	PubMed
38385506	RESULT	1	PubMed

1 to 10 of 1,552

See all 1,552 papers from its trials

Tests in its trials14

The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.

Test	Trials naming it as an outcome	As a primary outcome	Source
Stroop Color-Word Test	6	1	ConductCognition
Trail Making Test A	6	2	ConductCognition
Trail Making Test B	6	2	ConductCognition
Verbal Fluency	4	1	ConductCognition
Verbal Learning	4	3	ConductCognition
Picture Naming Test	3	1	ConductCognition
Category Fluency	2	0	ConductCognition
Clock Drawing Task	2	0	ConductCognition
Attention Network Test	1	0	ConductCognition
Balloon Risk	1	1	ConductCognition

1 to 10 of 14

See all 14 tests in its trials

Data dates

The date of each source this release read.

Open Targets: 2026-09-18; Open Targets
ClinicalTrials.gov: 2026-11-05; ClinicalTrials.gov
Results, from AACT: 2026-03-23; AACT
Papers the trials list, from Trials: 2026-11-12; Trials
Comparisons, from Trial comparisons: 2026-03-23; Trial comparisons
Tests named in the trials, as ScienceGraph matched them: 2026-11-12; ConductCognition

Sources 7

ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
ChEMBL, through Open TargetsCC BY-SA 3.0
ConductCognition's list of its testsOur own data
ClinicalTrials.govNo license stated
NLM's MeSHNLM's terms
Open TargetsCC0 1.0
PubMedNLM's terms

Each source's terms

ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
ClinicalTrials.govnone stated
NLM's MeSHNLM's
Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
PubMedNLM's terms

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this drug from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/drugs/v1/CHEMBL25

GET https://conductscience.org/api/drugs/v1/CHEMBL25/diseases?page=2

API reference For AI assistants